Partner
Trinity Innovation (Beijing) Investment Management Co., Ltd
Trinity Innovation (Beijing) Investment Management Co., Ltd is an investment institution focusing on the field of biomedical innovation. Before starting the company, Dr. Yin Served as the managing director of SDIC Innovation Investment Management Co., Ltd., responsible for equity investment in the pharmaceutical and healthcare sector, such as Dizal, Ribo, Ascentage, CanSino, Bright-gene, Ribo and EpimAb. Dr. Yin Worked in both biotech and global multinational pharmaceutical companies Novartis, responsible for innovative drug discovery and project management; Previous positions include Dean of the School of Pharmacy of Nankai University, Deputy Director of the State Key Laboratory of Medicinal Chemical Biology, and Executive Director of the Center for Basic Molecular Science of Tsinghua University. He has been employed as a member of several national industry and science and technology professional committees. Dr. Yin Zheng also served as the PWC Investment and M&A of Consulting Director, and carried out investment and M &A consulting business in the Biomedical Industry.
Bachelor and Master degree from Nankai University; Ph.D. of Science, National University of Singapore.